In contrast, blockage of CES1 activity by pharmacological or genetic approaches impairs mitochondrial function, increases ROS production, and decreases the levels of SCD, thereby sensitizing HCC to chemotherapeutic agents, such as cisplatin and sorafenib (Figure 8, right). Here, CES1 is linked to hepatocellular carcinoma.